Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Abstract
The global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of HPV-related diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by HPV-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protects from certain type of human papillomavirus. It protects against either two, four or nine kinds of HPV. The other factors supporting the market’s growth are, the increasing research for therapeutic vaccine, large number of clinical trials, increasing awareness and government investments, ease in approval of new HPV vaccines, and growing need to reduce HPV infections.
Increasing cases of Human Papillomavirus Diseases among the Population
Upsurge in the cases of HPV related diseases such as anal, oropharynx, and genital parts and growing demand for HPV vaccines, are projecting to propel the growth of the market, globally. There are just three types of vaccines in the market: bivalent, tetravalent, and nonavalent. All the three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in U.S, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of HPV. Moreover, in women, cervical cancer is very common among age between 9 to 30, which spur the need for HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer is liable for over 2,50,000 deaths of women globally and 85% of these deaths occur in developing countries.
Increasing Initiatives by Government & Private Organizations
Over the past few years, governments of different nations and private organizations are taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments on research and development, increase in awareness programs, extensive research actives and clinical trials and ease in approvals by the regulatory bodies, are the supporting factors for the market. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in process to develop GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven HPV kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.

Market Segmentation
The global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is divided into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising prevalence of HPV-related diseases and better healthcare infrastructure in the country.
Market Players
Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.


Report Scope:
In this report, global human papillomavirus vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
•Human Papillomavirus Vaccine Market, By Valence:
oBivalent
oQuadrivalent
oNonvalent
oOthers
•Human Papillomavirus Vaccine Market, By Disease Indication:
oCervical Cancer
oAnal Cancer
oVaginal Cancer
oPenile Cancer
oVulvar Cancer
oOthers
•Human Papillomavirus Vaccine Market, By Distribution Channel:
oHospitals & Clinics
oGovernmental & Non-Governmental Organizations
oPublic & Private Alliances
oOthers
•Human Papillomavirus Vaccine Market, By Region:
oNorth America
United States
Canada
Mexico
oAsia-Pacific
China
India
Japan
Australia
South Korea
oEurope & CIS
Germany
France
United Kingdom
Spain
Italy
oSouth America
Brazil
Argentina
Colombia
oMiddle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape

Competitive Landscape Detailed analysis of the major companies present in Human Papillomavirus Vaccine Market

Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
•Detailed analysis and profiling of additional market players (up to five).

Content
Table of Contents

1.Product Overview
2.Research Methodology
3.Impact of COVID-19 on Global Human Papillomavirus Vaccine Market
4.Voice of Customer
5.Executive Summary
6.Clinical Trial Analysis
7.Patent Analysis
8.Global Human Papillomavirus Vaccine Market Outlook
8.1.Market Size & Forecast
8.1.1.By Value
8.2.Market Share & Forecast
8.2.1.By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
8.2.2.By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
8.2.3.By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
8.2.4.By Company (2021)
8.2.5.By Region
8.3.Market Map
9.North America Human Papillomavirus Vaccine Market Outlook
9.1.Market Size & Forecast
9.1.1.By Value
9.2.Market Share & Forecast
9.2.1.By Valence
9.2.2.By Disease Indication
9.2.3.By Distribution Channel
9.2.4.By Country
9.3.North America: Country Analysis
9.3.1.United States Human Papillomavirus Vaccine Market Outlook
9.3.1.1.Market Size & Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share & Forecast
9.3.1.2.1.By Valence
9.3.1.2.2.By Disease Indication
9.3.1.2.3.By Distribution Channel
9.3.2.Mexico Human Papillomavirus Vaccine Market Outlook
9.3.2.1.Market Size & Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share & Forecast
9.3.2.2.1.By Valence
9.3.2.2.2.By Disease Indication
9.3.2.2.3.By Distribution Channel
9.3.3.Canada Human Papillomavirus Vaccine Market Outlook
9.3.3.1.Market Size & Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share & Forecast
9.3.3.2.1.By Valence
9.3.3.2.2.By Disease Indication
9.3.3.2.3.By Distribution Channel
10.Europe Human Papillomavirus Vaccine Market Outlook
10.1.Market Size & Forecast
10.1.1.By Value
10.2.Market Share & Forecast
10.2.1.By Valence
10.2.2.By Disease Indication
10.2.3.By Distribution Channel
10.2.4.By Country
10.3.Europe: Country Analysis
10.3.1.France Human Papillomavirus Vaccine Market Outlook
10.3.1.1.Market Size & Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share & Forecast
10.3.1.2.1.By Valence
10.3.1.2.2.By Disease Indication
10.3.1.2.3.By Distribution Channel
10.3.2.Germany Human Papillomavirus Vaccine Market Outlook
10.3.2.1.Market Size & Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share & Forecast
10.3.2.2.1.By Valence
10.3.2.2.2.By Disease Indication
10.3.2.2.3.By Distribution Channel
10.3.3.United Kingdom Human Papillomavirus Vaccine Market Outlook
10.3.3.1.Market Size & Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share & Forecast
10.3.3.2.1.By Valence
10.3.3.2.2.By Disease Indication
10.3.3.2.3.By Distribution Channel
10.3.4.Italy Human Papillomavirus Vaccine Market Outlook
10.3.4.1.Market Size & Forecast
10.3.4.1.1.By Value
10.3.4.2.Market Share & Forecast
10.3.4.2.1.By Valence
10.3.4.2.2.By Disease Indication
10.3.4.2.3.By Distribution Channel
10.3.5.Spain Human Papillomavirus Vaccine Market Outlook
10.3.5.1.Market Size & Forecast
10.3.5.1.1.By Value
10.3.5.2.Market Share & Forecast
10.3.5.2.1.By Valence
10.3.5.2.2.By Disease Indication
10.3.5.2.3.By Distribution Channel
11.Asia-Pacific Human Papillomavirus Vaccine Market Outlook
11.1.Market Size & Forecast
11.1.1.By Value
11.2.Market Share & Forecast
11.2.1.By Valence
11.2.2.By Disease Indication
11.2.3.By Distribution Channel
11.2.4.By Country
11.3.Asia-Pacific: Country Analysis
11.3.1.China Human Papillomavirus Vaccine Market Outlook
11.3.1.1.Market Size & Forecast
11.3.1.1.1.By Value
11.3.1.2.Market Share & Forecast
11.3.1.2.1.By Valence
11.3.1.2.2.By Disease Indication
11.3.1.2.3.By Distribution Channel
11.3.2.India Human Papillomavirus Vaccine Market Outlook
11.3.2.1.Market Size & Forecast
11.3.2.1.1.By Value
11.3.2.2.Market Share & Forecast
11.3.2.2.1.By Valence
11.3.2.2.2.By Disease Indication
11.3.2.2.3.By Distribution Channel
11.3.3.Japan Human Papillomavirus Vaccine Market Outlook
11.3.3.1.Market Size & Forecast
11.3.3.1.1.By Value
11.3.3.2.Market Share & Forecast
11.3.3.2.1.By Valence
11.3.3.2.2.By Disease Indication
11.3.3.2.3.By Distribution Channel
11.3.4.South Korea Human Papillomavirus Vaccine Market Outlook
11.3.4.1.Market Size & Forecast
11.3.4.1.1.By Value
11.3.4.2.Market Share & Forecast
11.3.4.2.1.By Valence
11.3.4.2.2.By Disease Indication
11.3.4.2.3.By Distribution Channel
11.3.5.Australia Human Papillomavirus Vaccine Market Outlook
11.3.5.1.Market Size & Forecast
11.3.5.1.1.By Value
11.3.5.2.Market Share & Forecast
11.3.5.2.1.By Valence
11.3.5.2.2.By Disease Indication
11.3.5.2.3.By Distribution Channel
12.South America Human Papillomavirus Vaccine Market Outlook
12.1.Market Size & Forecast
12.1.1.By Value
12.2.Market Share & Forecast
12.2.1.By Valence
12.2.2.By Disease Indication
12.2.3.By Distribution Channel
12.2.4.By Country
12.3.South America: Country Analysis
12.3.1.Brazil Human Papillomavirus Vaccine Market Outlook
12.3.1.1.Market Size & Forecast
12.3.1.1.1.By Value
12.3.1.2.Market Share & Forecast
12.3.1.2.1.By Valence
12.3.1.2.2.By Disease Indication
12.3.1.2.3.By Distribution Channel
12.3.2.Argentina Human Papillomavirus Vaccine Market Outlook
12.3.2.1.Market Size & Forecast
12.3.2.1.1.By Value
12.3.2.2.Market Share & Forecast
12.3.2.2.1.By Valence
12.3.2.2.2.By Disease Indication
12.3.2.2.3.By Distribution Channel
12.3.3.Colombia Human Papillomavirus Vaccine Market Outlook
12.3.3.1.Market Size & Forecast
12.3.3.1.1.By Value
12.3.3.2.Market Share & Forecast
12.3.3.2.1.By Valence
12.3.3.2.2.By Disease Indication
12.3.3.2.3.By Distribution Channel
13.Middle East and Africa Human Papillomavirus Vaccine Market Outlook
13.1.Market Size & Forecast
13.1.1.By Value
13.2.Market Share & Forecast
13.2.1.By Valence
13.2.2.By Disease Indication
13.2.3.By Distribution Channel
13.2.4.By Country
13.3.MEA: Country Analysis
13.3.1.South Africa Human Papillomavirus Vaccine Market Outlook
13.3.1.1.Market Size & Forecast
13.3.1.1.1.By Value
13.3.1.2.Market Share & Forecast
13.3.1.2.1.By Valence
13.3.1.2.2.By Disease Indication
13.3.1.2.3.By Distribution Channel
13.3.2.Saudi Arabia Human Papillomavirus Vaccine Market Outlook
13.3.2.1.Market Size & Forecast
13.3.2.1.1.By Value
13.3.2.2.Market Share & Forecast
13.3.2.2.1.By Valence
13.3.2.2.2.By Disease Indication
13.3.2.2.3.By Distribution Channel
13.3.3.UAE Human Papillomavirus Vaccine Market Outlook
13.3.3.1.Market Size & Forecast
13.3.3.1.1.By Value
13.3.3.2.Market Share & Forecast
13.3.3.2.1.By Valence
13.3.3.2.2.By Disease Indication
13.3.3.2.3.By Distribution Channel
14.Market Dynamics
14.1.Drivers
14.2.Challenges
15.Market Trends & Developments
16.Competitive Landscape
16.1.Serum Institute of India Pvt. Ltd.
16.2.GlaxoSmithKline Plc.
16.3.Johnson & Johnson
16.4.Merck & Co., Inc.
16.5.AstraZeneca Plc
16.6.Novartis AG
16.7.Inovio Pharmaceuticals, Inc.
16.8.Xenetic Biosciences, Inc.
16.9.Sanofi SA
16.10.Bharat Biotech International Limited
17.Strategic Recommendations